Alyssa M Cates1, Victoria I Holden1, Emily M Myers1, Carolyne K Smith1, Mariana J Kaplan1, J Michelle Kahlenberg2. 1. Department of Internal Medicine, Division of Rheumatology, Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI and Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Disorders, National Institutes of Health, Bethesda, MD, USA. 2. Department of Internal Medicine, Division of Rheumatology, Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI and Systemic Autoimmunity Branch, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Disorders, National Institutes of Health, Bethesda, MD, USA mkahlenb@med.umich.edu.
Abstract
OBJECTIVE: SLE is an autoimmune disease characterized by autoantibody generation, organ damage and an increased risk of cardiovascular disease. Generally considered an anti-inflammatory cytokine, IL-10 is increased in SLE and correlates with poor cardiovascular outcomes in the general population. The aim of this study was to explore the putative role of IL-10 in modulating endothelial function in SLE by examining the effects of this cytokine on endothelial progenitor cell/circulating angiogenic cell (EPC/CAC) differentiation. METHODS: Human and murine control and lupus EPCs/CACs were differentiated into mature endothelial cells (ECs) in the presence or absence of graded concentrations of recombinant IL-10 with or without recombinant IFN-α or a neutralizing antibody to IL-10. IL-10-deficient mice were examined to assess the role of this cytokine in type I IFN-mediated inhibition of EC differentiation and neo-angiogenesis using an in vivo Matrigel plug assay. Serum IL-10 concentrations were measured via ELISA. RESULTS: IL-10 hampers EC differentiation in a dose-dependent manner. In murine EPC cultures, IL-10 is required to observe the inhibitory effects of type I IFNs on EPC function and neo-angiogenesis. In human SLE EPC/CAC cultures, neutralization of IL-10 significantly improved the differentiation of EPCs, and IL-10 enhanced type I IFN-mediated EPC/CAC dysfunction. The presence of IL-10 in serum inversely correlated with EPC/CAC function in SLE but not in control cells. CONCLUSION: IL-10 interferes with endothelial differentiation and may enhance the effects of type I IFN on vascular repair in SLE. IL-10 may be a relevant target for improving cardiovascular risk in SLE.
OBJECTIVE:SLE is an autoimmune disease characterized by autoantibody generation, organ damage and an increased risk of cardiovascular disease. Generally considered an anti-inflammatory cytokine, IL-10 is increased in SLE and correlates with poor cardiovascular outcomes in the general population. The aim of this study was to explore the putative role of IL-10 in modulating endothelial function in SLE by examining the effects of this cytokine on endothelial progenitor cell/circulating angiogenic cell (EPC/CAC) differentiation. METHODS:Human and murine control and lupus EPCs/CACs were differentiated into mature endothelial cells (ECs) in the presence or absence of graded concentrations of recombinant IL-10 with or without recombinant IFN-α or a neutralizing antibody to IL-10. IL-10-deficient mice were examined to assess the role of this cytokine in type I IFN-mediated inhibition of EC differentiation and neo-angiogenesis using an in vivo Matrigel plug assay. Serum IL-10 concentrations were measured via ELISA. RESULTS:IL-10 hampers EC differentiation in a dose-dependent manner. In murine EPC cultures, IL-10 is required to observe the inhibitory effects of type I IFNs on EPC function and neo-angiogenesis. In humanSLE EPC/CAC cultures, neutralization of IL-10 significantly improved the differentiation of EPCs, and IL-10 enhanced type I IFN-mediated EPC/CAC dysfunction. The presence of IL-10 in serum inversely correlated with EPC/CAC function in SLE but not in control cells. CONCLUSION:IL-10 interferes with endothelial differentiation and may enhance the effects of type I IFN on vascular repair in SLE. IL-10 may be a relevant target for improving cardiovascular risk in SLE.
Authors: S Manzi; E N Meilahn; J E Rairie; C G Conte; T A Medsger; L Jansen-McWilliams; R B D'Agostino; L H Kuller Journal: Am J Epidemiol Date: 1997-03-01 Impact factor: 4.897
Authors: Z Mallat; S Besnard; M Duriez; V Deleuze; F Emmanuel; M F Bureau; F Soubrier; B Esposito; H Duez; C Fievet; B Staels; N Duverger; D Scherman; A Tedgui Journal: Circ Res Date: 1999-10-15 Impact factor: 17.367
Authors: Christian Ehlting; Wi S Lai; Fred Schaper; Erwin D Brenndörfer; Raphaela-Jessica Matthes; Peter C Heinrich; Stephan Ludwig; Perry J Blackshear; Matthias Gaestel; Dieter Häussinger; Johannes G Bode Journal: J Immunol Date: 2007-03-01 Impact factor: 5.422
Authors: Mariana J Kaplan; Massimo Gadina; Yasuko Furumoto; Carolyne K Smith; Luz Blanco; Wenpu Zhao; Stephen R Brooks; Seth G Thacker; Zarzour Abdalrahman; Giuseppe Sciumè; Wanxia L Tsai; Anna M Trier; Leti Nunez; Laurel Mast; Victoria Hoffmann; Alan T Remaley; John J O'Shea Journal: Arthritis Rheumatol Date: 2017-01 Impact factor: 10.995
Authors: Felecia M Marottoli; Yuriko Katsumata; Kevin P Koster; Riya Thomas; David W Fardo; Leon M Tai Journal: ASN Neuro Date: 2017 Jul-Aug Impact factor: 4.146
Authors: Chiara Crotti; Maria Gabriella Raimondo; Andrea Becciolini; Martina Biggioggero; Ennio Giulio Favalli Journal: Drug Des Devel Ther Date: 2017-01-13 Impact factor: 4.162
Authors: Dag Leonard; Elisabet Svenungsson; Johanna Dahlqvist; Andrei Alexsson; Lisbeth Ärlestig; Kimberly E Taylor; Johanna K Sandling; Christine Bengtsson; Martina Frodlund; Andreas Jönsen; Susanna Eketjäll; Kerstin Jensen-Urstad; Iva Gunnarsson; Christopher Sjöwall; Anders A Bengtsson; Maija-Leena Eloranta; Ann-Christine Syvänen; Solbritt Rantapää-Dahlqvist; Lindsey A Criswell; Lars Rönnblom Journal: Ann Rheum Dis Date: 2018-03-07 Impact factor: 19.103
Authors: Devandir Antonio de Souza Junior; Antonio Carlos Borges; Ana Carolina Santana; Constance Oliver; Maria Célia Jamur Journal: PLoS One Date: 2015-12-03 Impact factor: 3.240